MannKind Corp
MNKDHealthcare|Biotechnology|USA
$4.09
-0.05 (-1.21%)
Upcoming Data Readouts (2)
Mar 2027
Est. completion
P2Type 1 Diabetes Mellitus
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
NCT07224321n=100
Jan 2028
Est. completion
P2Idiopathic Pulmonary Fibrosis
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
NCT07679893n=210